- Details
- 68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was FDA approved on December 1, 2020. The approval was granted to the University of California–San Francisco (UCSF) and UC–Los Angeles (UCLA). 68 Ga-PSMA-11 is indicated for suspected metastatic disease at the time of initial staging prior to definitive ther...
|
- Details
- Prostate Cancer Outreach Webinar - Hosted by The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Prostate Cancer Working Group, and faculty from the University of California, San Francisco (UCSF) Molecular imaging and radionuclide therapies play an important role in the management of patients with prostate cancer. Recent advances are allowing for increased precision in both diagnosis a...
|
- Details
- Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer. Correct localization rate (CLR), or the positive predictive value of the PyL scan, was established as the primary endpoint and the C...
|
- Details
- Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study "A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy." Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localized prostate canc...
|
- Details
- Phillip Koo interviews Jeremie Calais about PSMA PET imaging in patients with localized prostate cancer. Professor Calais discusses the advantages of whole-body PSMA PET imaging in patients with presumed localized cancer, as well as those likely to have extraprostatic disease. The PSMA whole-body imaging modality can be used to identify cancer lesions with high sensitivity in patients. PSMA PET is...
|
- Details
- Anwar Padhani discusses his presentation from the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) on the flare phenomenon in advanced prostate cancer. Because of this phenomenon, clinicians have created workarounds. Dr. Padhani expands that there are multiple consequences of the workarounds, one being that they cause delays in the treatment schedule. Precision oncology trials require ra...
|
- Details
- Mike Machaba Sathekge, MD, PhD presents on the power of medicine, specifically targeted radionuclide therapies and the use of actinium-225 in advanced prostate cancer. Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. He discusses the initial experience with 225Ac-PSMA-617 in a deve...
|
- Details
- Howard Soule discusses highlights and his takeaways from the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Soule highlights the importance of coming to these conferences to understand where the gaps are in the treatment landscape and the benefit of these global conferences for clinicians from resource-limited countries. They continue on to discuss imaging, PSMA, and the VISION tr...
|
- Details
- Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care. Biographies: Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES...
|
- Details
- Stefano Fanti reviews the consensus paper on nuclear imaging for prostate cancer which was recently published in Lancet Oncology in December 2018. PSMA PET should be offered early in biochemical recurrence as it is the most sensitive and the EAU has incorporated PSMA PET into their guidelines as well, recommending PSMA PET for PSA >0.2. Stefano and Alicia discuss the various PSMA technologies and...
|
